Chronic Leukemias

Chronic Leukemias

A collection of features and news articles published in ASH Clinical News related to chronic leukemias.

WIB_icon

BTKi Improves Disease Control in CLL After Progression on Venetoclax

Treatment with a Bruton tyrosine kinase inhibitor (BTKi) showed efficacy in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) that progressed on venetoclax, according to...
On location

Interim Results of Randomized Comparison of Ponatinib Starting Doses in Chronic-Phase CML

Response-based ponatinib dosing demonstrated clinical benefit in patients with resistant chronic-phase chronic myeloid leukemia (CML) with rate of arterial occlusive (AO) events that did...

Demystifying PCR-Based Molecular Monitoring in CML

When imatinib, the first tyrosine kinase inhibitor (TKI), was approved for the treatment of chronic myeloid leukemia (CML) in 2001, the disease’s natural history...
On location

Study Examines Trends in Real-World Treatment Sequencing Patterns for CLL/SLL

The availability of B-cell receptor inhibitors (BCRis) and other novel agents for the treatment of chronic lymphocytic leukemia (CLL) has reshaped the treatment paradigm...

Outcomes With Idelalisib Differ in the Clinical Trial Versus Real-World Setting

According to a real-world analysis published in JAMA Oncology, treatment outcomes with idelalisib differed between patients with follicular lymphoma (FL) and chronic lymphocytic leukemia...

Zanubrutinib Active in Patients with Treatment-Naive Del17p CLL/SLL

Approximately 93% of patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and del17p responded to treatment with the next-generation Bruton tyrosine kinase (BTK)...

Is Chemoimmunotherapy for Upfront CLL on Life Support?

For years, standard of care first-line treatment for chronic lymphocytic leukemia (CLL) included the FCR (fludarabine, cyclophosphamide, rituximab) chemoimmunotherapy regimen. However, the past decade...

Acalabrutinib Treatment Superior to Obinutuzumab Plus Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia

Acalabrutinib, alone or combined with obinutuzumab, led to greater improvements in progression-free survival (PFS), compared with obinutuzumab plus chlorambucil, in patients with treatment-naïve chronic...

Asciminib Shows Durable Clinical Activity in Heavily Pretreated CML

In a phase I, dose-escalation study, treatment with asciminib was active and associated with durable responses in more than half of patients with chronic...

Defining the Goals of Venetoclax Treatment in Relapsed/Refractory CLL

Achieving undetectable measurable residual disease (MRD) predicts a better clinical outcome in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who are treated with venetoclax,...
Advertisement

Current Issue

June 2020, Volume 6, Issue 7

This issue explores COVID-19-associated coagulopathy, features frequently asked questions from oncologists, and more.